Accessibility Tools

Continuing treatment not beneficial after five years of bisphosphonates

Source: Medical Xpress

For women who have received five years of bisphosphonate therapy, hip fracture risk does not differ with continuing treatment for an additional five years versus discontinuing treatment, according to a study published online Dec. 7 in JAMA Network Open.

Read More

  • Sigma Sigma Phi Honor Fraternity
  • American Osteopathic Board of Orthopedic Surgery
  • Oklahoma State University College of Osteopathic Medicine
  • American Board of Psychiatry and Neurology